Because an oral 15-PGDH inhibitor has already passed Phase 1 safety testing in humans for age-related #muscle weakness, the authors are hopeful that clinical trials in joint disease will follow, potentially paving the way for #nonsurgical, cartilage-regenerating therapies that could delay or replace knee and hip replacements
The patient shown above sent us a selfie of her bruising after her first treatment (please forgive the poor quality, she took this on her own in a mirror, so were thankful that we have it to show to you, but its not the best quality)
However, its low toxicity , strong safety profile in animal studies, and lack of severe side effects have made it one of the most accessible peptides for first-time users interested in soft tissue recovery
If your dose is 5 units or fewer, a 50-unit syringe can help you measure more accurately
The licensed instruction is unambiguous
Oregano - In vitro study